STRO 250117 5.00P (STRO250117P5000) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayClose Dec 26 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Dec 10 07:09

NEWS

$Sutro Biopharma (STRO.US)$
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
Tuesday, 10th December at 8:00 am
- 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial -
- These data confirm luvelta's robust response rate in patients with late-stage ovarian c...

Trytosaveabit

Nov 1 07:03

Update

$Sutro Biopharma (STRO.US)$ Reuters· 2 mins ago
Sutro Biopharma Announces Initiation of the Registration-Enabling RefrΑMe-P1 Trial With Luvelta for Pediatric Patients With Cbf/Glis Aml

Jaguar8

Nov 1 07:02

NEWS

$Sutro Biopharma (STRO.US)$
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
Sutro Biopharma has initiated REFRαME-P1, a registration-enabling trial of luveltamab tazevibulin (luvelta) for pediatric patients with CBF/GLIS AML. The study follows encouraging compassionate use data presented in December 2023, showing 42% complete remission in patients with ≥5% blasts. CBF/GLIS AML is a rare, aggressive leuke...

Jaguar8

Oct 10 15:06

NEWS

$Sutro Biopharma (STRO.US)$
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
Sutro Biopharma (NASDAQ: STRO) is hosting an investor webcast to showcase its proprietary cell-free platform and next-generation ADC innovation. The company highlights three approaches: increasing potency safely with higher drug-antibody ratio exatecan ADCs, combining payloads to overcome tumor resistance with dual-payload ADCs (ADC2), and delivering immunostimulatory...

Jaguar8

Sep 14 02:03

WEEKEND NEWS

$Sutro Biopharma (STRO.US)$
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
Sutro Biopharma (NASDAQ: STRO) announced updated data from its Phase 1b study of luveltamab tazevibulin (luvelta) in combination with bevacizumab for epithelial ovarian cancer (EOC) at ESMO 2024. Key findings include:
- 56% objective response rate at the recommended phase 2 dose (RP2D) of 4.3 mg/kg luvelta with 15 mg/kg bevacizumab
- 35% overal...